The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition
Scandinavian Journal of Immunology · 2023
DOI: 10.1111/sji.13304 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2023. Verfasst von Jiajun Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China (81902898, 81700660, 81772696, 81974393), Shanghai Sailing Program (19YF1407900), Experimental Animal Project of Shanghai Science and Technology Commission (19140905200).
Abstract (Originalsprache)
Checkpoint inhibitor immunotherapy plus tyrosine kinase inhibitor (IO/TKI) has become the first‐line treatment for metastatic renal cell carcinoma (RCC), despite the lack of biomarkers. Cyclin‐dependent kinase 6 (CDK6) has shown a regulatory role in antitumour response. The study enrolled two cohorts of metastatic RCC treated by IO/TKI (Zhongshan Hospital [ZS]‐MRCC, n = 45; JAVELIN‐101, n = 726) and two cohorts of localized RCC (ZS‐HRRCC, n = 40; TCGA‐KIRC, n = 530). CDK6 was evaluated by RNA‐sequencing. Progression‐free survival (PFS) was the primary endpoint. The prognostic role of CDK6 was evaluated by survival analysis. The correlation between CDK6 and tumour microenvironment was assessed by immunohistochemistry and flow cytometry. The high‐CDK6 group displayed a lower response rate (13.6%) than the low‐CDK6 group (56.5%) ( P = .002). High‐CDK6 was associated with poor PFS in both the ZS‐MRCC cohort (high‐CDK6, median PFS 6.4 months; low‐CDK6, median PFS not reached; P = .010) and JAVELIN‐101 cohort (high‐CDK6, median PFS 10.0 months; low‐CDK6, median PFS 13.3 month; P = .033). High‐CDK6 was associated with increased PD1 + CD8 + T cells (Spearman's ρ = .47, P < .001) and decreased Granzyme B + CD8 + T cells (Spearman's ρ = −.35, P = .030). Finally, a random forest score (RFscore) was built by integrating CDK6 and immunologic genes, which was associated with survival benefits of IO/TKI (RFscore‐low, TKI vs IO/TKI, HR = 2.47, 95% CI 1.82–3.35, P < .001; RFscore‐high, TKI vs IO/TKI, HR = 0.99, 95% CI 0.75–1.32, P = .963). Elevated CDK6 expression indicated resistance and poor PFS under IO/TKI therapy, which was related to exhausted CD8 + T cells. Integrated RFscore could evaluate the benefits of IO/TKI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Jiajun Wang, Sihong Zhang, Ying Wang, Yanjun Zhu, Xianglai Xu, Jianming Guo
Förderung
- National Natural Science Foundation of China (81902898, 81700660, 81772696, 81974393)
- Shanghai Sailing Program (19YF1407900)
- Experimental Animal Project of Shanghai Science and Technology Commission (19140905200)
Zitieren
APA
Wang, J., Zhang, S., Wang, Y., Zhu, Y., Xu, X., & Guo, J. (2023). The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.13304
Vancouver
Wang J, Zhang S, Wang Y, Zhu Y, Xu X, Guo J. The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition. Scandinavian Journal of Immunology. 2023. doi:10.1111/sji.13304
BibTeX
@article{Wang2023,
author = {Wang, Jiajun and Zhang, Sihong and Wang, Ying and Zhu, Yanjun and Xu, Xianglai and Guo, Jianming},
title = {The prognostic significance of CDK6 expression in renal cell carcinoma treated by immune checkpoint plus tyrosine kinase inhibition},
journal = {Scandinavian Journal of Immunology},
year = {2023},
doi = {10.1111/sji.13304}
}
EUVIMED